Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 103

1.

SPARC promotes leukemic cell growth and predicts acute myeloid leukemia outcome.

Alachkar H, Santhanam R, Maharry K, Metzeler KH, Huang X, Kohlschmidt J, Mendler JH, Benito JM, Hickey C, Neviani P, Dorrance AM, Anghelina M, Khalife J, Tarighat SS, Volinia S, Whitman SP, Paschka P, Hoellerbauer P, Wu YZ, Han L, Bolon BN, Blum W, Mrózek K, Carroll AJ, Perrotti D, Andreeff M, Caligiuri MA, Konopleva M, Garzon R, Bloomfield CD, Marcucci G.

J Clin Invest. 2014 Apr;124(4):1512-24. doi: 10.1172/JCI70921. Epub 2014 Mar 3.

2.

Intronic miR-3151 within BAALC drives leukemogenesis by deregulating the TP53 pathway.

Eisfeld AK, Schwind S, Patel R, Huang X, Santhanam R, Walker CJ, Markowitz J, Hoag KW, Jarvinen TM, Leffel B, Perrotti D, Carson WE 3rd, Marcucci G, Bloomfield CD, de la Chapelle A.

Sci Signal. 2014 Apr 15;7(321):ra36. doi: 10.1126/scisignal.2004762.

3.

SPARC silencing inhibits the growth of acute myeloid leukemia transformed from myelodysplastic syndrome via induction of cell cycle arrest and apoptosis.

Nian Q, Xiao Q, Wang L, Luo J, Chen LP, Yang ZS, Liu L.

Int J Mol Med. 2014 Apr;33(4):856-62. doi: 10.3892/ijmm.2014.1648. Epub 2014 Feb 7.

4.

IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study.

Marcucci G, Maharry K, Wu YZ, Radmacher MD, Mrózek K, Margeson D, Holland KB, Whitman SP, Becker H, Schwind S, Metzeler KH, Powell BL, Carter TH, Kolitz JE, Wetzler M, Carroll AJ, Baer MR, Caligiuri MA, Larson RA, Bloomfield CD.

J Clin Oncol. 2010 May 10;28(14):2348-55. doi: 10.1200/JCO.2009.27.3730. Epub 2010 Apr 5.

5.

Amplified HMGA2 promotes cell growth by regulating Akt pathway in AML.

Tan L, Wei X, Zheng L, Zeng J, Liu H, Yang S, Tan H.

J Cancer Res Clin Oncol. 2016 Feb;142(2):389-99. doi: 10.1007/s00432-015-2036-9. Epub 2015 Aug 30.

PMID:
26319392
6.

Regulation of the MIR155 host gene in physiological and pathological processes.

Elton TS, Selemon H, Elton SM, Parinandi NL.

Gene. 2013 Dec 10;532(1):1-12. doi: 10.1016/j.gene.2012.12.009. Epub 2012 Dec 14. Review.

PMID:
23246696
7.

Expression of PIM-2 and NF-κB genes is increased in patients with acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) and is associated with complete remission rate and overall survival.

Kapelko-Słowik K, Urbaniak-Kujda D, Wołowiec D, Jaźwiec B, Dybko J, Jakubaszko J, Słowik M, Kuliczkowski K.

Postepy Hig Med Dosw (Online). 2013 Jun 7;67:553-9.

8.

Favorable prognostic impact of NPM1 mutations in older patients with cytogenetically normal de novo acute myeloid leukemia and associated gene- and microRNA-expression signatures: a Cancer and Leukemia Group B study.

Becker H, Marcucci G, Maharry K, Radmacher MD, Mrózek K, Margeson D, Whitman SP, Wu YZ, Schwind S, Paschka P, Powell BL, Carter TH, Kolitz JE, Wetzler M, Carroll AJ, Baer MR, Caligiuri MA, Larson RA, Bloomfield CD.

J Clin Oncol. 2010 Feb 1;28(4):596-604. doi: 10.1200/JCO.2009.25.1496. Epub 2009 Dec 21.

9.

SPARC regulates TGF-beta1-dependent signaling in primary glomerular mesangial cells.

Francki A, McClure TD, Brekken RA, Motamed K, Murri C, Wang T, Sage EH.

J Cell Biochem. 2004 Apr 1;91(5):915-25.

PMID:
15034927
10.

IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication.

Paschka P, Schlenk RF, Gaidzik VI, Habdank M, Krönke J, Bullinger L, Späth D, Kayser S, Zucknick M, Götze K, Horst HA, Germing U, Döhner H, Döhner K.

J Clin Oncol. 2010 Aug 1;28(22):3636-43. doi: 10.1200/JCO.2010.28.3762. Epub 2010 Jun 21.

PMID:
20567020
11.

MicroRNA-9 promotes proliferation of leukemia cells in adult CD34-positive acute myeloid leukemia with normal karyotype by downregulation of Hes1.

Tian C, You MJ, Yu Y, Zhu L, Zheng G, Zhang Y.

Tumour Biol. 2016 Jun;37(6):7461-71. doi: 10.1007/s13277-015-4581-x. Epub 2015 Dec 17.

PMID:
26678889
12.

Prognostic importance of MN1 transcript levels, and biologic insights from MN1-associated gene and microRNA expression signatures in cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B study.

Langer C, Marcucci G, Holland KB, Radmacher MD, Maharry K, Paschka P, Whitman SP, Mrózek K, Baldus CD, Vij R, Powell BL, Carroll AJ, Kolitz JE, Caligiuri MA, Larson RA, Bloomfield CD.

J Clin Oncol. 2009 Jul 1;27(19):3198-204. doi: 10.1200/JCO.2008.20.6110. Epub 2009 May 18.

13.

SPARC ectopic overexpression inhibits growth and promotes programmed cell death in acute myeloid leukemia transformed from myelodysplastic syndrome cells, alone and in combination with Ara-C treatment.

Nian Q, Chi J, Xiao Q, Wei C, Costeas P, Yang Z, Liu L, Wang L.

Oncol Rep. 2015 Sep;34(3):1406-14. doi: 10.3892/or.2015.4114. Epub 2015 Jul 8.

PMID:
26165695
14.

Pharmacological targeting of miR-155 via the NEDD8-activating enzyme inhibitor MLN4924 (Pevonedistat) in FLT3-ITD acute myeloid leukemia.

Khalife J, Radomska HS, Santhanam R, Huang X, Neviani P, Saultz J, Wang H, Wu YZ, Alachkar H, Anghelina M, Dorrance A, Curfman J, Bloomfield CD, Medeiros BC, Perrotti D, Lee LJ, Lee RJ, Caligiuri MA, Pichiorri F, Croce CM, Garzon R, Guzman ML, Mendler JH, Marcucci G.

Leukemia. 2015 Oct;29(10):1981-92. doi: 10.1038/leu.2015.106. Epub 2015 May 14.

15.

c-Myc suppresses miR-451⊣YWTAZ/AKT axis via recruiting HDAC3 in acute myeloid leukemia.

Su R, Gong JN, Chen MT, Song L, Shen C, Zhang XH, Yin XL, Ning HM, Liu B, Wang F, Ma YN, Zhao HL, Yu J, Zhang JW.

Oncotarget. 2016 Nov 22;7(47):77430-77443. doi: 10.18632/oncotarget.12679.

16.

Prognostic significance of, and gene and microRNA expression signatures associated with, CEBPA mutations in cytogenetically normal acute myeloid leukemia with high-risk molecular features: a Cancer and Leukemia Group B Study.

Marcucci G, Maharry K, Radmacher MD, Mrózek K, Vukosavljevic T, Paschka P, Whitman SP, Langer C, Baldus CD, Liu CG, Ruppert AS, Powell BL, Carroll AJ, Caligiuri MA, Kolitz JE, Larson RA, Bloomfield CD.

J Clin Oncol. 2008 Nov 1;26(31):5078-87. doi: 10.1200/JCO.2008.17.5554. Epub 2008 Sep 22. Erratum in: J Clin Oncol. 2008 Dec 20;26(36):6021.

17.

A TIM-3/Gal-9 Autocrine Stimulatory Loop Drives Self-Renewal of Human Myeloid Leukemia Stem Cells and Leukemic Progression.

Kikushige Y, Miyamoto T, Yuda J, Jabbarzadeh-Tabrizi S, Shima T, Takayanagi S, Niiro H, Yurino A, Miyawaki K, Takenaka K, Iwasaki H, Akashi K.

Cell Stem Cell. 2015 Sep 3;17(3):341-52. doi: 10.1016/j.stem.2015.07.011. Epub 2015 Aug 13.

18.
19.

Acquired expression of osteopontin selectively promotes enrichment of leukemia stem cells through AKT/mTOR/PTEN/β-catenin pathways in AML cells.

Mohammadi S, Ghaffari SH, Shaiegan M, Zarif MN, Nikbakht M, Akbari Birgani S, Alimoghadam K, Ghavamzadeh A.

Life Sci. 2016 May 1;152:190-8. doi: 10.1016/j.lfs.2016.04.003. Epub 2016 Apr 7.

PMID:
27063991
20.

A novel molecular pathway for Snail-dependent, SPARC-mediated invasion in non-small cell lung cancer pathogenesis.

Grant JL, Fishbein MC, Hong LS, Krysan K, Minna JD, Shay JW, Walser TC, Dubinett SM.

Cancer Prev Res (Phila). 2014 Jan;7(1):150-60. doi: 10.1158/1940-6207.CAPR-13-0263. Epub 2013 Nov 19.

Supplemental Content

Support Center